Kybella

Now you can non-surgically improve your chin profile

 

What is Kybella? Kybella™ is a:

  • Prescription medicine used in adults to improve the appearance and profile of moderate to severe fat below the chin (submental fat), also called “double chin.”
  • Nonsurgical, 15- to 20-minute in-office treatment session—customized to help you achieve your treatment goals 

What is submental fullness?

  • Submental fullness due to submental fat, sometimes referred to as "double chin", is a common, yet undertreated facial aesthetic condition. It can detract from an otherwise balanced and harmonious facial appearance, leading to an older and heavier look. 
  • Submental fullness can impact a broad range of adults, and is not limited to people who are overweight. This condition can impact men or women of average weight and can be caused by aging, genetics and weight gain. It is often resistant to diet and exercise alone.
  • According to a 2014 survey by the American Society for Dermatologic Surgery (ASDS), over 2/3 of consumers are bothered by submental fullness—nearly as many as those bothered by lines and wrinkles around the eyes.

 

 

How Does Kybella™ (deoxycholic acid) Injection Work? 

  •  The active ingredient in Kybella™ is deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. 
  •  When injected into the fat beneath your chin, Kybella™ causes the destruction of fat cells. 
  • Once destroyed, those cells cannot store or accumulate fat.
  •  Many patient treated with Kybella™ experienced visible contouring of their chin profile in 2 to 4 treatments.
  •  Up to 6 treatments may be administered.
  • Once the aesthetic goal is achieved, retreatment is not expected. 
  •  The most common side effects of Kybella™ include swelling, bruising, pain, numbness, redness, and areas of hardness in the treatment area. 

 

 

How many people have been treated with Kybella™ and what were the results?

  • Kybella™ has been the focus of a global clinical development program involving over 20 clinical studies with more than 2,600 patients worldwide, of which over 1,600 have been treated with Kybella™ 
  • In clinical studies, 28%, 43% and 55% of Kybella™-treated patients had an improvement after 2, 3 and 4 treatments, respectively. 

Link to this page for more information http://consumers.mykybella.com/